Key Segmentation
By Treatment Type
-
Pharmacological Therapies
-
Ketamine & Esketamine Therapies
-
Neuromodulation Therapies (TMS, DBS, VNS)
-
Psychedelic-Assisted Therapies
-
Digital & Combination Therapies
By Drug / Therapy Class
-
SSRIs & SNRIs Augmentation
-
Atypical Antipsychotic Augmentation
-
NMDA Receptor Modulators
-
Neuromodulation Therapies
-
Emerging Novel Therapies
By Route of Administration
-
Oral
-
Intranasal
-
Intravenous
-
Device-Based Treatment
-
Others
By End User
-
Hospitals
-
Psychiatric Clinics
-
Specialty Mental Health Centers
-
Academic & Research Institutes
-
Home-Based & Digital Care Providers
-
Others
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The Treatment-Resistant Depression (TRD) Treatment Market was valued at USD 2.28 billion in 2025.
The market is projected to reach USD 5.56 billion by 2035.
The market is expected to expand at a CAGR of 9.33% during the forecast period.
North America dominated the global market in 2025.
Asia Pacific is expected to register the fastest CAGR during the forecast period.